Cargando…

Abstract 129: Continuous glucose monitoring in type 2 diabetes mellitus to assess glycemic control and glycemic variability

Background: Continuous glucose monitoring (CGM) can provide information beyond HbA1c and SMBG for glycemic control. Objectives: To assess glycemic variability (GV) and correlation of CGM metrics with HbA1c in type 2 diabetic (T2DM) individuals. Results: We enrolled 54 T2DM patients (age 53±7.8 years...

Descripción completa

Detalles Bibliográficos
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer - Medknow 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9067792/
http://dx.doi.org/10.4103/2230-8210.342254
_version_ 1784700085444018176
collection PubMed
description Background: Continuous glucose monitoring (CGM) can provide information beyond HbA1c and SMBG for glycemic control. Objectives: To assess glycemic variability (GV) and correlation of CGM metrics with HbA1c in type 2 diabetic (T2DM) individuals. Results: We enrolled 54 T2DM patients (age 53±7.8 years) on prior 3-month stable anti-diabetic medications for atleast 48-hours CGM (IPRO®2 Professional) with satisfactory agreement with glucometer cross-calibration. With 892.4±192.1 CGM readings, there was good correlation between CGM parameters and HbA1c (mean±SD- 9.45±2.57%) using Spearman's rho (π) analysis. There was positive correlation with HbA1c of glucose management indicator (GMI) (π=0.777, p<0.001), time-above-range (TAR) (π=0.739, p<0.001), area under curve (AUC) above limit (π=0.707, p<0.001), and negative correlation of Time-in-range (TIR) (π=-0.716, p<0.001). Looking into GV, there was no significant correlation of coefficient-of-variation (CV%) (π=-0.265, p=0.055) and weak positive correlation of standard deviation (SD) (π=0.274, p= 0.043) with HbA1c. More importantly, Time-below-range (TBR) ≥ 4% was seen in 8 (14.8%) patients, thus detecting unidentified asymptomatic hypoglycemias in 6 (11.1%) patients. Conclusions: Most CGM metrics correlated well with HbA1c, with additional advantage of identifying glycemic variability and asymptomatic hypoglycemias, These can be missed by infrequent home SMBG and HbA1c, and using CGM metrics can help tailor therapy to achieve a more optimal glycemic control, even in patients with relatively well-controlled HbA1c.
format Online
Article
Text
id pubmed-9067792
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Wolters Kluwer - Medknow
record_format MEDLINE/PubMed
spelling pubmed-90677922022-05-05 Abstract 129: Continuous glucose monitoring in type 2 diabetes mellitus to assess glycemic control and glycemic variability Indian J Endocrinol Metab Abstracts … Esicon 2021 Background: Continuous glucose monitoring (CGM) can provide information beyond HbA1c and SMBG for glycemic control. Objectives: To assess glycemic variability (GV) and correlation of CGM metrics with HbA1c in type 2 diabetic (T2DM) individuals. Results: We enrolled 54 T2DM patients (age 53±7.8 years) on prior 3-month stable anti-diabetic medications for atleast 48-hours CGM (IPRO®2 Professional) with satisfactory agreement with glucometer cross-calibration. With 892.4±192.1 CGM readings, there was good correlation between CGM parameters and HbA1c (mean±SD- 9.45±2.57%) using Spearman's rho (π) analysis. There was positive correlation with HbA1c of glucose management indicator (GMI) (π=0.777, p<0.001), time-above-range (TAR) (π=0.739, p<0.001), area under curve (AUC) above limit (π=0.707, p<0.001), and negative correlation of Time-in-range (TIR) (π=-0.716, p<0.001). Looking into GV, there was no significant correlation of coefficient-of-variation (CV%) (π=-0.265, p=0.055) and weak positive correlation of standard deviation (SD) (π=0.274, p= 0.043) with HbA1c. More importantly, Time-below-range (TBR) ≥ 4% was seen in 8 (14.8%) patients, thus detecting unidentified asymptomatic hypoglycemias in 6 (11.1%) patients. Conclusions: Most CGM metrics correlated well with HbA1c, with additional advantage of identifying glycemic variability and asymptomatic hypoglycemias, These can be missed by infrequent home SMBG and HbA1c, and using CGM metrics can help tailor therapy to achieve a more optimal glycemic control, even in patients with relatively well-controlled HbA1c. Wolters Kluwer - Medknow 2022-03 /pmc/articles/PMC9067792/ http://dx.doi.org/10.4103/2230-8210.342254 Text en Copyright: © 2022 Indian Journal of Endocrinology and Metabolism https://creativecommons.org/licenses/by-nc-sa/4.0/This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.
spellingShingle Abstracts … Esicon 2021
Abstract 129: Continuous glucose monitoring in type 2 diabetes mellitus to assess glycemic control and glycemic variability
title Abstract 129: Continuous glucose monitoring in type 2 diabetes mellitus to assess glycemic control and glycemic variability
title_full Abstract 129: Continuous glucose monitoring in type 2 diabetes mellitus to assess glycemic control and glycemic variability
title_fullStr Abstract 129: Continuous glucose monitoring in type 2 diabetes mellitus to assess glycemic control and glycemic variability
title_full_unstemmed Abstract 129: Continuous glucose monitoring in type 2 diabetes mellitus to assess glycemic control and glycemic variability
title_short Abstract 129: Continuous glucose monitoring in type 2 diabetes mellitus to assess glycemic control and glycemic variability
title_sort abstract 129: continuous glucose monitoring in type 2 diabetes mellitus to assess glycemic control and glycemic variability
topic Abstracts … Esicon 2021
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9067792/
http://dx.doi.org/10.4103/2230-8210.342254